JP7660074B2 - Ｈｅｒ２抗体の組み合わせ物 - Google Patents

Ｈｅｒ２抗体の組み合わせ物 Download PDF

Info

Publication number
JP7660074B2
JP7660074B2 JP2021564926A JP2021564926A JP7660074B2 JP 7660074 B2 JP7660074 B2 JP 7660074B2 JP 2021564926 A JP2021564926 A JP 2021564926A JP 2021564926 A JP2021564926 A JP 2021564926A JP 7660074 B2 JP7660074 B2 JP 7660074B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence shown
region comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021564926A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530272A5 (enExample
JP2022530272A (ja
Inventor
フィッシャー、シュテファン
Original Assignee
エムエービー ディスカバリー ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エムエービー ディスカバリー ゲーエムベーハー filed Critical エムエービー ディスカバリー ゲーエムベーハー
Publication of JP2022530272A publication Critical patent/JP2022530272A/ja
Publication of JP2022530272A5 publication Critical patent/JP2022530272A5/ja
Application granted granted Critical
Publication of JP7660074B2 publication Critical patent/JP7660074B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021564926A 2019-05-02 2020-04-29 Ｈｅｒ２抗体の組み合わせ物 Active JP7660074B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19172329.5 2019-05-02
EP19172329 2019-05-02
PCT/EP2020/061850 WO2020221791A1 (en) 2019-05-02 2020-04-29 Combination of her2 antibodies

Publications (3)

Publication Number Publication Date
JP2022530272A JP2022530272A (ja) 2022-06-28
JP2022530272A5 JP2022530272A5 (enExample) 2023-04-21
JP7660074B2 true JP7660074B2 (ja) 2025-04-10

Family

ID=66625743

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021564926A Active JP7660074B2 (ja) 2019-05-02 2020-04-29 Ｈｅｒ２抗体の組み合わせ物

Country Status (7)

Country Link
US (1) US20220204644A1 (enExample)
EP (1) EP3962525A1 (enExample)
JP (1) JP7660074B2 (enExample)
CN (1) CN113924116B (enExample)
AU (1) AU2020266253A1 (enExample)
CA (1) CA3137480A1 (enExample)
WO (1) WO2020221791A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4345113A1 (en) 2022-09-30 2024-04-03 SDS Optic Spolka Akcyjna Anti-her2 antibody, a nucleic acid molecule encoding the variable region of said antibody, a method of detecting her2 in a biological sample, an immuno-enzymatic elisa assay and use of said anti-her2 antibody or fragments therefof
CN117224689B (zh) * 2023-11-16 2024-02-23 上海复宏汉霖生物技术股份有限公司 联合抗her2抗体和化疗剂治疗胃癌的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540460A (ja) 2007-09-24 2010-12-24 トラガラ ファーマシューティカルズ，インク． ＣＯＸ‐２阻害薬と抗ＨＥＲ２［ＥｒｂＢ２］抗体の混合物又はＣＯＸ‐２阻害薬とＨＥＲ２［ＥｒｂＢ２］受容体チロシンキナーゼ阻害薬の混合物を用いた癌の治療
JP2013534809A (ja) 2010-05-27 2013-09-09 ゲンマブ エー／エス Ｈｅｒ２エピトープに対するモノクローナル抗体
JP2016518368A (ja) 2013-05-16 2016-06-23 アブクロン・インコーポレイテッドＡｂｃｌｏｎ Ｉｎｃ． Ｈｅｒ２に特異的に結合できる抗体
WO2017191327A2 (en) 2016-05-06 2017-11-09 Mab Discovery Gmbh Her-2 binding antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0812682A2 (pt) * 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2016022723A1 (en) * 2014-08-05 2016-02-11 Merrimack Pharmaceuticals, Inc. Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies
US20180271996A1 (en) * 2017-02-28 2018-09-27 Mersana Therapeutics, Inc. Combination therapies of her2-targeted antibody-drug conjugates
PT3589661T (pt) * 2017-03-02 2024-01-29 Genentech Inc Tratamento com adjuvante de cancro da mama positivo para her2

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540460A (ja) 2007-09-24 2010-12-24 トラガラ ファーマシューティカルズ，インク． ＣＯＸ‐２阻害薬と抗ＨＥＲ２［ＥｒｂＢ２］抗体の混合物又はＣＯＸ‐２阻害薬とＨＥＲ２［ＥｒｂＢ２］受容体チロシンキナーゼ阻害薬の混合物を用いた癌の治療
JP2013534809A (ja) 2010-05-27 2013-09-09 ゲンマブ エー／エス Ｈｅｒ２エピトープに対するモノクローナル抗体
JP2016518368A (ja) 2013-05-16 2016-06-23 アブクロン・インコーポレイテッドＡｂｃｌｏｎ Ｉｎｃ． Ｈｅｒ２に特異的に結合できる抗体
WO2017191327A2 (en) 2016-05-06 2017-11-09 Mab Discovery Gmbh Her-2 binding antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cancer Res.，2009年，vol.69, no.24，p.9330-9336
J. Clin. Oncol.，2010年，vol.28，p.1138-1144
J. Transl. Med.，2020年，vol.18, no.1，article 316

Also Published As

Publication number Publication date
CN113924116B (zh) 2025-11-25
CA3137480A1 (en) 2020-11-05
US20220204644A1 (en) 2022-06-30
JP2022530272A (ja) 2022-06-28
CN113924116A (zh) 2022-01-11
EP3962525A1 (en) 2022-03-09
AU2020266253A1 (en) 2021-10-21
WO2020221791A1 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
JP7171617B2 (ja) 抗ＳＩＲＰα抗体
AU2020289179B2 (en) Binding molecule specific for CD73 and use of binding molecule
JP7038462B2 (ja) ヒト化抗ｉｌ－１ｒ３抗体
JP7754895B2 (ja) アゴニスト性ｃｄ４０抗体
US12129307B2 (en) HER-2 binding antibodies
CN115461366B (zh) 抗ox40抗体及其用途
JP7660074B2 (ja) Ｈｅｒ２抗体の組み合わせ物
US20260115307A1 (en) Anti-fucosyl-gm1 antibody drug conjugates
WO2026096695A1 (en) Anti-fucosyl-gm1 antibody drug conjugates
HK40085344A (en) Anti-ox40 antibody and uses thereof
HK40085822A (en) Anti-ox40 antibody and uses thereof
HK40029748A (en) Agonistic cd40 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211208

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20211208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230413

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240312

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240611

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250304

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250331

R150 Certificate of patent or registration of utility model

Ref document number: 7660074

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150